Actor Pharmaceuticals and Megalabs Collaborate with Formycon to commercialize FYB203 (Biosimilar, Eylea) in Australia and LATAM 

Shots: 

• Formycon has reported that Klinge Biopharma, holder of global rights to its FYB203 (biosimilar, Eylea), has granted exclusive commercialization rights to Actor Pharmaceuticals for Australia and to Megalabs for LATAM. Regulatory filing is submitted to Australia’s TGA, and Formycon is preparing approval applications with Megalabs for LATAM 

• As per the deal, Klinge will receive upfront and milestone payments, plus royalties, with Formycon sharing in these payments (in the mid-single- to low-double-digit range). Formycon will also manage FYB203 supply and earn service fees and a volume-based profit share  

• Eylea (aflibercept) treats nAMD and other retinal diseases by inhibiting VEGF-driven abnormal blood vessel growth 

Ref: Formycon | Image: Formycon  | Press Release

Related News:- Formycon and Klinge Biopharma sign a semi-exclusive licensing deal with Horus Pharma to commercialize the FYB203/Baiama (Biosimilar, Eylea)  

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com